Navigation Links
MetaChip provides quick, efficient toxicity screening of potential drugs

A large, multisite trial designed to examine the safety and preliminary effectiveness of two candidate topical microbicides to prevent HIV infection has opened to volunteer enrollment. The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, represents a partnership among various research institutions in Africa and the United States.

Although no licensed microbicides are available to the public currently, scientists hope these agents--designed to be applied to the surface of the vagina to prevent sexually transmitted infections (STIs)--will one day be a key tool in the fight against HIV/AIDS.

Women make up nearly half of all people living with HIV worldwide. "The majority of new cases of HIV infection in women result from heterosexual intercourse, but women may not always be able to insist that their male partners use measures to prevent HIV transmission," notes NIAID Director Anthony S. Fauci, M.D. "If effective, microbicides would be a valuable woman-controlled means of slowing the pace of the HIV/AIDS epidemic," Dr. Fauci adds.

The first volunteers were enrolled this week at sites in Durban, South Africa, and at the University of Pennsylvania in Philadelphia. Enrollment will begin shortly at sites in four additional African countries--Malawi, Tanzania, Zimbabwe and Zambia. Approximately 3,220 women will be enrolled in the trial, which is expected to last approximately 30 months.

"This is the first microbicide safety and effectiveness trial of this magnitude to be conducted by NIAID," says Roberta J. Black, Ph.D., Topical Microbicide Team Leader in NIAID's Division of AIDS. "It is a critical trial evaluating two topical microbicides with differing mechanisms of action," she adds.

The microbicides to be tested are PRO 2000 and BufferGel. Produced by Indevus Pharmaceuticals, Lexington, MA, PRO 2000 has shown activity against HIV and other STIs in both laboratory and animal testing. It is believed to act by inhibiting the entry of HIV and other pathogens into body cells. BufferGel, a product of ReProtect, Inc., Baltimore, MD, boosts the natural acidity of the vagina in the presence of seminal fluid that neutralizes the vaginal environment. An acidic environment inactivates HIV as well as other pathogens.

Each woman in the trial will be placed at random into one of four equally sized groups. One group will use BufferGel before each act of sexual intercourse, one group will use PRO 2000, one group will use a placebo gel, and the final group will not use any gel. In addition, all participants will receive condoms and extensive prevention counseling at each clinic visit.

The trial is one of numerous studies conducted through NIH's HIV Prevention Trials Network (HPTN), which is funded by NIAID, the National Institute of Child Health and Human Development, the National Institute on Drug Abuse and the National Institute of Mental Health. More information about this study (HPTN 035) is available at www.hptn.org/index.htm. The protocol chair of the study is Salim Abdool Karim, MBChB, Ph.D., of the University of KwaZulu-Natal in Durban, South Africa.


'"/>

Source:


Related biology news :

1. NYU and MSKCC research provides model for understanding chemically induced cancer initiation
2. Nature provides inspiration for important new adhesive
3. New plant DNA libraries provides massive boost to worlds plant researchers
4. NASA satellite data provides rapid analysis of Amazon deforestation
5. Study provides insight into cellular defenses against genetic mutation
6. Customized gene chip provides rapid detection of genetic changes in childrens cancer
7. Vaccine provides 100 percent protection against avian flu virus in animal study
8. New hybrid virus provides targeted molecular imaging of cancer
9. Ancient DNA provides clues to the evolution of social behavior
10. Brittlestar provides new model for stem cell research
11. Use of amino acid supplement following a heart attack provides no benefit, may be harmful
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... April 20, 2017 For today, Stock-Callers.com ... novel drug development and clinical research aimed at treating diseases ... (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. ... ). You can access our complimentary research reports on these ... ...
(Date:4/19/2017)... ... , ... Alisa Wright, founder and CEO of Singota Solutions , has ... in Lafayette, Indiana. , The Distinguished Alumni Award was established in 1984 to ... scientific endeavors. , Wright began her career in the pharmaceutical industry with firms ...
(Date:4/19/2017)... ... April 19, 2017 , ... ThermaGenix, the PCR ... event adds to several other early achievements at ThermaGenix, including the business formation ... , ThermaGenix will use proceeds from the Series A-1 round to:, ...
(Date:4/19/2017)... and PUNE, India , April 19, 2017 /PRNewswire/ ... "Membrane Microfiltration Market: Global Opportunity Analysis and Industry Forecast, 2014-2022 ," the global ... $12,858 million by 2022, registering a CAGR of 9.6% from 2016 to 2022. ... ... ...
Breaking Biology Technology: